Veru Inc (VERU)

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (HDRN)

Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU...

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities